Healthcare
Atrium Therapeutics, Inc.(RNA)
Live Price
Offline$12.16
+4.20% today
1Y Change
-56.98%
Window
Jun 20, 2025 โ Jun 16, 2026
- Market Cap
- $210.00M
- Revenue Growth
- 0.0%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 20, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Atrium Therapeutics, Inc. (RNA) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $12.16 and down 57.0% across the available one-year price window (Jun 20, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin -412.6% and ROIC -31.9%. Valuation already assumes a fairly strong business story at price/sales 11.2. Stock Foundry combines RNA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-412.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is 0.0%, while operating margin sits near -412.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged -40.2% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -0.3% | -1.7% | -6.8% |
2026 Feb 26, 2026 | +35.5% | -79.7% | -78.8% | -82.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RNA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RNA Max Drawdown
-84.16%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RNA and SPY.
Company Overview
Atrium Therapeutics, Inc.
NASDAQ Global Select
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
- Leadership
- Kathleen Gallagher
- IPO Date
- Feb 27, 2026
- Employees
- 511
- Street Address
- 10578 Science Center Drive
- Mailing
- San Diego, CA, 92121
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 619 876 0700
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.8
- Price/Sales
- 11.2
- Price/Book
- 1.1
Growth
- Revenue
- 0.0%
- EPS
- 0.0%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -412.6%
- Net Margin
- -411.9%
- ROE
- -37.0%
- ROIC
- -31.9%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 6.53
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.